Abstract:Objective: Although the mechanisms behind pharmacokinetic (PK) drug-drug interactions (DDIs) are well-documented, bridging the gap between this knowledge and clinical evidence of DDIs, especially for serious adverse drug reactions (SADRs), remains challenging. While leveraging the FDA Adverse Event Reporting System (FAERS) database along with disproportionality analysis tends to detect a vast number of DDI signals, this abundance complicates further investigation, such as validation through clinical trials. Our study proposed a framework to efficiently prioritize these signals and assessed their reliability using multi-source Electronic Health Records (EHR) to identify top candidates for further investigation. Methods: We analyzed FAERS data spanning from January 2004 to March 2023, employing four established disproportionality methods: Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), Multi-item Gamma Poisson Shrinker (MGPS), and Bayesian Confidence Propagating Neural Network (BCPNN). Building upon these models, we developed four ranking models to prioritize DDI-SADR signals and cross-referenced signals with DrugBank. To validate the top-ranked signals, we employed longitudinal EHRs from Vanderbilt University Medical Center and the All of Us research program. The performance of each model was assessed by counting how many of the top-ranked signals were confirmed by EHRs and calculating the average ranking of these confirmed signals. Results: Out of 189 DDI-SADR signals identified by all four disproportionality methods, only two were documented in the DrugBank database. By prioritizing the top 20 signals as determined by each of the four disproportionality methods and our four ranking models, 58 unique DDI-SADR signals were selected for EHR validations. Of these, five signals were confirmed. The ranking model, which integrated the MGPS and BCPNN, demonstrated superior performance by assigning the highest priority to those five EHR-confirmed signals. Conclusion: The fusion of disproportionality analysis with ranking models, validated through multi-source EHRs, presents a groundbreaking approach to pharmacovigilance. Our study's confirmation of five significant DDI-SADRs, previously unrecorded in the DrugBank database, highlights the essential role of advanced data analysis techniques in identifying ADRs.

Changing paradigms in detecting rare adverse drug reactions: from disproportionality analysis, old and new, to machine learning

Study of Serious Adverse Drug Reactions Using FDA-approved Drug Labeling and MedDRA

Developing A Deep Learning Natural Language Processing Algorithm For Automated Reporting Of Adverse Drug Reactions

A New Era in Pharmacovigilance: Toward Real‐World Data and Digital Monitoring

Detecting Potential Serious Adverse Drug Reactions Using Sequential Pattern Mining Method

Establishment of a Rapid Identification of Adverse Drug Reaction Program in R Language Implementation Based on Monitoring Data

Filtering Big Data from Social Media - Building an Early Warning System for Adverse Drug Reactions

Discovering clinical drug-drug interactions with known pharmacokinetics mechanisms using spontaneous reporting systems and electronic health records

Investigating the Benefit-Risk Profile of Drugs: From Spontaneous Reporting Systems to Real-World Data for Pharmacovigilance

Exploiting heterogeneous publicly available data sources for drug safety surveillance: computational framework and case studies

Detecting high-quality signals of adverse drug-drug interactions from spontaneous reporting data

Dealing with adverse drug reactions in the context of polypharmacy using regression models

Application of Association Rules Analysis in Mining Adverse Drug Reaction Signals

Artificial intelligence-powered pharmacovigilance: A review of machine and deep learning in clinical text-based adverse drug event detection for benchmark datasets

An Empirical Approach to Explore the Relationship Between Measures of Disproportionate Reporting and Relative Risks from Analytical Studies

Identification of Novel Signals Associated with US-FDA Approved Drugs (2013) Using Disproportionality Analysis

Abstract 4923: A systematic framework for predicting adverse drug reaction signals using medical data

Detecting Pharmacovigilance Signals Combining Electronic Medical Records With Spontaneous Reports: A Case Study of Conventional Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis

Methods for drug safety signal detection using routinely collected observational electronic health care data: a systematic review

Statistical Techniques for Signal Generation

Statistical and Graphical Approaches for Disproportionality Analysis of Spontaneously-Reported Adverse Events in Pharmacovigilance